SELLAS Life Sciences Group, Inc.(SLS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $9.3M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SLS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for SELLAS Life Sciences Group, Inc. (SLS), a Healthcare sector company. SLS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $9.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), SELLAS Life Sciences Group, Inc. reports net income of $-8.4M, free cash flow of $-8.8M. Top institutional holders of SLS by reported 13-F value include BlackRock,, STATE STREET, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. SLS trades on the Nasdaq exchange and files with the SEC under CIK 1390478. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SELLAS Life Sciences Group, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-8.4M
Free Cash Flow
Q1 2026
$-8.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+13.0% YoYOperating Income
+10.3% YoYEPS (Diluted)
+50.0% YoYTotal Assets
+303.2% YoYOp. Cash Flow
+19.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 -100.0% | $7.6M +300.0% | $1.9M | $0.00 |
| Net Income | $-26.9M +13.0% | $-30.9M +17.3% | $-37.3M -80.4% | $-20.7M -23.5% | $-16.8M +13.1% | $-19.3M |
| Operating Income | $-28.3M +10.3% | $-31.5M +16.8% | $-37.9M -49.7% | $-25.3M -48.9% | $-17.0M +15.3% | $-20.0M |
| EPS (Diluted) | $-0.25 +50.0% | $-0.50 +62.7% | $-1.34 +0.0% | $-1.34 +36.5% | $-2.11 | — |
| Total Assets | $78.3M +303.2% | $19.4M +212.5% | $6.2M -76.3% | $26.3M -42.9% | $46.0M +177.3% | $16.6M |
| Operating Cash Flow | $-28.4M +19.8% | $-35.4M -12.7% | $-31.4M -20.7% | $-26.0M -149.8% | $-10.4M +41.0% | $-17.6M |
AI Insight: SLS Ratio Trends
SELLAS is progressively narrowing losses across all return metrics, with ROE improving from -178.9% in Q3 2024 to -31.3% in Q1 2026.
• ROE recovered from -178.9% (Q3 2024) to -31.3% (Q1 2026), a 147.6pp improvement over nine months.
• ROA similarly improved from -66.5% (Q1 2025) to -29.4% (Q1 2026), showing sustained progress in asset efficiency despite negative returns.
• TTM ROE/ROA/ROIC remain deeply negative at -27.4% / -25.8% / -29.3%, indicating the company remains unprofitable on a rolling basis.
⚠ Trajectory of profitability—company must cross into positive returns to validate turnaround narrative; current path suggests potential breakeven within 2–3 quarters if trend holds.
⚠ No margin, leverage, or cash-flow data available; inability to assess operational efficiency, balance-sheet health, or runway complicates risk assessment.
Get alerted when SLS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SELLAS Life Sciences Group, Inc. including:
Top Institutional Holders of SLS
BlackRock, Inc.
$51.6M12,198,410 shSTATE STREET CORP
$35.5M8,396,356 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$32.2M7,624,100 shVANGUARD CAPITAL MANAGEMENT LLC
$31.8M7,525,929 shCITADEL ADVISORS LLC
$18.5M4,368,200 shGEODE CAPITAL MANAGEMENT, LLC
$16.6M3,912,606 shMARSHALL WACE, LLP
$8.6M2,037,162 shJONES FINANCIAL COMPANIES LLLP
$7.3M1,675,077 shVANGUARD PORTFOLIO MANAGEMENT LLC
$6.2M1,462,806 shMORGAN STANLEY
$5.7M1,336,293 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $51.6M | 12,198,410 |
| STATE STREET CORP | $35.5M | 8,396,356 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32.2M | 7,624,100 |
| VANGUARD CAPITAL MANAGEMENT LLC | $31.8M | 7,525,929 |
| CITADEL ADVISORS LLC | $18.5M | 4,368,200 |
| GEODE CAPITAL MANAGEMENT, LLC | $16.6M | 3,912,606 |
| MARSHALL WACE, LLP | $8.6M | 2,037,162 |
| JONES FINANCIAL COMPANIES LLLP | $7.3M | 1,675,077 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.2M | 1,462,806 |
| MORGAN STANLEY | $5.7M | 1,336,293 |
More Healthcare Companies
View all Healthcare →Put SLS on your watchlist
Track score changes the day SELLAS Life Sciences Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SLS a good stock to buy?
13F Pro's AI-powered analysis of SELLAS Life Sciences Group, Inc. (SLS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SLS are available on the SLS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SLS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SLS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SELLAS Life Sciences Group, Inc.'s investment landscape.